The Future of Lethal Injection Is Being Debated at the Supreme Court. Read These 6 Stories Now.

<a href="">David Hills</a>/iStock

For indispensable reporting on the coronavirus crisis, the election, and more, subscribe to the Mother Jones Daily newsletter.

Same-sex marriage is not the only major item on the Supreme Court’s docket this week: Today, the court will begin considering the future of a drug used in lethal injections. The suit, Glossip v. Gross, was brought by three Oklahoma inmates sentenced to death and challenges the use of the sedative Midazolam. The inmates’ lawyers argue that the drug—used in the botched execution of Clayton Lockett, who gasped for air and writhed in pain for a prolonged period as he was put to death—violates the Eighth Amendment’s protection from cruel and unusual punishment.

While only four states currently administer Midazolam, a Supreme Court ruling upholding its use could lead more states to employ the drug in executions. An opposite ruling could make lethal injection, and death penalty execution in general, rarer than it is now. Outlawing Midazolam, one of the few available lethal injection drugs, could leave states without any viable alternatives. Ahead of the oral arguments, read up on Mother Jones‘ best coverage of lethal injection and death penalty issues.


Headshot of Editor in Chief of Mother Jones, Clara Jeffery

It sure feels that way to me, and here at Mother Jones, we’ve been thinking a lot about what journalism needs to do differently, and how we can have the biggest impact.

We kept coming back to one word: corruption. Democracy and the rule of law being undermined by those with wealth and power for their own gain. So we're launching an ambitious Mother Jones Corruption Project to do deep, time-intensive reporting on systemic corruption, and asking the MoJo community to help crowdfund it.

We aim to hire, build a team, and give them the time and space needed to understand how we got here and how we might get out. We want to dig into the forces and decisions that have allowed massive conflicts of interest, influence peddling, and win-at-all-costs politics to flourish.

It's unlike anything we've done, and we have seed funding to get started, but we're looking to raise $500,000 from readers by July when we'll be making key budgeting decisions—and the more resources we have by then, the deeper we can dig. If our plan sounds good to you, please help kickstart it with a tax-deductible donation today.

Thanks for reading—whether or not you can pitch in today, or ever, I'm glad you're with us.

Signed by Clara Jeffery

Clara Jeffery, Editor-in-Chief

payment methods

We Recommend